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Abstract
Protein Misfolding Disorders (PMDs) are a group of diseases characterized by the accumulation of
abnormally folded proteins. Despite the wide range of proteins and tissues involved, PMDs share
similar molecular and pathogenic mechanisms. Several epidemiological, clinical and experimental
reports have described the co-existence of PMDs, suggesting a possible cross-talk between them. A
better knowledge of the molecular basis of PMDs could have important implications for
understanding the mechanism by which the diseases appear and progress and ultimately to develop
novel strategies for treatment. Due to their similar molecular mechanisms, common therapeutic
strategies could be applied for the diseases in this group.
MOLECULAR BASIS OF PROTEIN MISFOLDING DISORDERS
For a protein, the amino acid sequence is the blueprint that dictates the biologically active
conformation. However, throughout the life of the protein there are many factors that lead to
its unfolding and refolding, opening the door for a misfolding event to occur. This misfolding
event can lead to the aggregation of the misfolded protein into amyloids which then wreak
havoc on the body, leading to a variety of debilitating diseases. PMDs are a group of diverse,
fatal diseases resulting from the failure of a protein to fold into the correct conformation,
followed by its subsequent aggregation and deposition in tissues [1,2]. This group of diseases
comprises disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), transmissible
spongiform encephalopathies (TSEs) and type 2 diabetes among many others [2]. The
contribution of these aggregates to pathological decline is better understood in some of these
diseases; however their presence is a hallmark in all cases.
Transmissible Spongiform Encephalopathies
TSEs, also known as prion diseases, consist of a group of fatal neurodegenerative disorders
that are found in a variety of mammals. TSEs are the only PMDs known to be transmissible
by infection and the infectious agent (termed prion) is most likely composed exclusively of the
misfolded prion protein. During prion replication, the disease associated isoform of the prion
protein (PrPSc) imposes its three dimensional structure on the normal cellular form of the
protein (PrPC) resulting in the exponential accumulation and aggregation of PrPSc (Fig. 1)
[3,4]. A remarkable feature of these diseases is the prolonged incubation period followed by a
very rapid clinical phase that is invariably fatal. TSEs are unique diseases due to the tripartite
epidemiological appearance (inherited, sporadic, and acquired), and while rare in humans, with
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a sporadic Creutzfeldt Jacob Disease (sCJD) incidence of 1–2 cases per million persons per
year [5], they are more common in animals. TSEs can occur naturally or as a direct result of
the consumption of contaminated food. The recently described variant CJD (vCJD) resulted
from the consumption of meat infected with the bovine spongiform encephalopathy (BSE)
agent [6–8].
Prions, as other more conventional type of infectious agents, have two important properties:
prion strains and the species barrier phenomenon [9,10]. Prion strains are characterized
classically by their stable pathological and biochemical characteristics, including incubation
time in susceptible animals, clinical symptoms, and by their lesion profile in the central nervous
system [9]. While it is not entirely clear how strain characteristics are encoded, most data
indicates that the folding of PrPSc is responsible [11–13]. However, recent evidence suggests
that quaternary structure also likely has an influence on strain properties [14].
The species barrier phenomenon in TSEs describes the ability of prions from one species to
cause disease in another [15,16]. Initial passage of prions from one species to another can be
associated with complete resistance or long incubation times with 100% attack rate or less
followed by a large drop in the incubation period on subsequent passages with all animals
developing disease [17]. A clear example can be seen in the difficulty of hamster prions to
cause disease in wild type mice [18]. However, expression of hamster PrPC in transgenic mice
was shown to abolish this resistance [19]. Further experiments then demonstrated that the most
important determinant of the species barrier is the degree of homology between PrPC and
PrPSc [20]. Although this is thought to result in optimal prion transmission, prion strains have
been found to overcome the influence of primary structure [21]. One example of this is BSE,
which has been found to transmit to multiple species while having a primary structure that is
not identical to PrPC in the host [22–26]. This demonstrates that the factors controlling prion
transmission barriers likely work in combination rather than one factor dominating over the
others.
Mechanisms of Protein Misfolding and Seeded Aggregation
In each PMD, protein aggregates are composed of a misfolded protein unique to the disease,
such as amyloid β (Aβ peptide in AD or PrPSc in TSEs. The misfolded protein aggregates in
PMDs have similar characteristics, but vary in distribution and composition leading to different
deposition profiles and pathologies [2]. In addition, there are no sequence similarities between
the various proteins that are implicated in these disorders [2]. Protein aggregation is not a
random process, but occurs slowly through an ordered mechanism termed the nucleation-
dependent polymerization model [27,28].
The nucleation-dependent polymerization model features a slow and thermodynamically
unfavorable nucleation phase followed by a rapid elongation phase [28,29]. In the nucleation
phase, the rate-determining step is the formation of a stable seed or nucleus of polymerized
protein (Fig. 2). In vivo, the first seeds in this process can be formed spontaneously (as it is
mainly observed in TSEs, AD and PD), favored by mutations (as in Huntington’s disease) or
exogenously acquired (so far only accepted for TSEs). The seed can then simultaneously bind
to and convert multiple molecules of the normal protein, generating a thread of aggregated
small oligomers which subsequently will lead to the formation of amyloid fibrils and in some
cases, plaques [30] (Fig. 2). The dynamic distribution of these toxic species is characteristic
for each disease, but interestingly, it is also dependent on the specific conformation that the
proteins can acquire (i.e. as it is observed in different prion strains) [2,9]. Amyloid aggregates
are thought to be the triggering factors in various PMDs [30]. Amyloidogenic-specific dyes
such as Thioflavin T and Congo Red can be used to observe the kinetics of fibril formation
and have demonstrated that the length of the nucleation phase (or lag phase) and extension
phase are highly dependent on the protein concentration [2,30].
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The infectious nature of prions can be rationalized by the seeding-nucleation model [28]. While
the lag phase is normally a slow process, this phase can be reduced or eliminated by the addition
of a preformed seed or nucleus to serve as a template [31]. This would mean that in the case
of acquired prion diseases, such as vCJD or iatrogenic CJD, a PrPSc seed is introduced into the
body and used as a template to seed the polymerization of PrPSc aggregates, reducing the lag
phase and accelerating the elongation phase (Fig. 2). This provides a plausible explanation for
why vCJD appeared in much younger individuals, which is very different from the appearance
of disease late in life that occurs with the sporadic and inherited TSEs in which there is no
preformed seed introduced [6]. Since in vitro and in vivo evidence suggest that in all PMDs
the process of protein misfolding and aggregation also follow a seeding-nucleation mechanism
[29,32], it is possible that other PMDs might be transmissible following a similar route [29].
INTERACTION OF PMDS: FACT OR CHANCE?
The co-existence of various PMDs in the same individual has been extensively described
[33–35]. Moreover, the presence of two misfolded proteins has also been described in the same
amyloidogenic structure (see below). On this basis, it could be hypothesized that PMDs might
interact at the protein level through a process termed heterologous seeding or cross-seeding,
suggesting that one PMD could be an important risk factor for the development of a second
one.
Cross-Seeding
While it is well established that fibril formation is enhanced by adding preformed homologous
or heterologous seeds, it has also been shown in vitro that sequence similarity could have an
effect on seeding efficiency. By cross-seeding hen lysozyme with a series of proteins, it was
demonstrated that differing sequences had a lower efficiency of seeding [36]. In vivo studies
revealed that non-mammalian protein fibrils can cross-seed amyloid A protein in a murine
experimental amyloid A amyloidosis model [37]. In addition, several reports showing the co-
existence of different amyloid pathologies in the same tissue further support the existence of
cross-seeding as a disease mechanism [34,35,38–42]. This data suggests that one PMD may
be capable of influencing the development of another.
The demonstration that seeding with proteins of differing sequences has a lower efficiency is
reminiscent of the species barrier described earlier for TSEs. This could be a plausible
explanation for the low attack rate and long incubation periods typically observed during the
primary transmission of prions from one species to another [9,12,17,18]. However, there are
many other factors that could influence this phenomenon, such as the strain of the agent and
the genetic background of the host [43,44]. Nevertheless, recent experiments showing that the
species barrier phenomenon is reproduced in transgenic mice expressing PrP from different
species support the hypothesis that the sequence is the most important factor responsible for
this phenomenon [19,45–47].
CO-EXISTENCE OF PMDS
The study of a putative interaction of PMDs at the protein level is not only important from a
scientific point of view, but also for public health. A better understanding of this phenomenon
could explain the origin and prevalence of several PMDs. On the one hand, several of the
proteins related to these diseases are located in different cell compartments or cell types,
making a protein-protein interaction unlikely. On the other hand, the fact that some of these
proteins can increase their levels under certain pathological conditions enhances the possibility
of interaction between them. These events could be caused by several mechanisms which
include inflammation, overload of the proteasome and protein-chaperone mechanisms
(responsible for the elimination of misfolded proteins) and signaling cascades, among others.
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Such processes could interact, become synergic and enhance disease hallmarks (as misfolded
protein deposition) which could increase the chance of misfolded protein-protein interactions.
Next, we will discuss epidemiological and experimental data related to misfolded protein cross-
seeding and its putative role in the pathological progression.
Epidemiological Evidence
Probably the clearest evidence for the interaction of PMDs comes from the link between AD
and diabetes type-2, characterized by Aβ and amylin deposition, respectively. Clinical studies
had shown that a high percentage of patients affected with AD are also positive for diabetes
type-2 [48]. In 2004, Janson and co-workers showed that in a cohort of AD patients, 81% of
them had either diabetes type-2 or Impaired Fasting Glucose (IFG) [48]. In addition, and
comparing with age matched non-demented individuals, AD patients have a higher incidence
of islet amyloidosis than healthy individuals. However, this study described that Aβ deposition
is not increased in patients affected with diabetes type-2, suggesting that this phenomenon
could be unidirectional. Other reports have been published supporting or contradicting this
conclusion [49–54]. However, the location of amyloid proteins in different tissues and the lack
of reports showing the co-existence of both misfolded aggregates in the same organ question
the idea that the interaction between AD and diabetes type 2 is due to cross-seeding
mechanisms.
Other clinical examples are found in patients affected with PD and AD where the co-existence
of Aβ and α-synuclein has been described [33,55,56]. In this case, pathological features of both
diseases co-exist in the brain, increasing the probabilities that misfolded protein aggregates
can interact. Recently, Tsigelni et al. showed that α-synuclein and Aβ directly interact in the
brain of patients with Lewy body disease [55]. This report also describes patients clinically
diagnosed with AD presenting higher accumulations of α-synuclein compared to healthy
individuals. In addition, co-inmmunoprecipitation experiments using anti-Aβ antibodies
showed that brains from Lewy body disease patients presented strong anti-Aβ
immunoreactivity after analysis by Western blot [55].
The phenomenon of amyloids’ co-existence has been described for several other
amyloidogenic proteins. Among them, the simultaneous presence of Aβ and prions has been
extensively documented in patients affected with sCJD, Gerstmann-Sträussler-Scheinker
(GSS) disease and AD [34,35,39,57–60]. In some cases of AD, accumulation of PrP within
Aβ deposits occurs as diffuse plaques [57,60]. These aggregates are easily eliminated after
proteinase K treatment on brain slides, suggesting that prion aggregates are composed in part
or totally by PrPC or by protease-sensitive PrPSc. These findings are similar to what is observed
for double transgenic mice over-expressing amyloid precursor protein with Swedish and
Indiana mutations (associated with strong Aβ deposition) and hamster PrP [61]. However, due
to the high density of PrP in these areas, the possibility of de novo PrPSc generation should be
considered. In addition, it is important to mention that many cases of TSEs are associated with
proteinase K sensitive PrPSc [62–64], which could be mainly composed of oligomeric protease-
sensitive species.
Several cases of sCJD and GSS patients with plaques composed of misfolded PrP and Aβ have
been reported [34,35,39,58,59]. A recent study shows that a subgroup of sCJD patients show
higher levels of Aβ42 in their brains [58]. As a consequence, Aβ plaques were found in the
brain of these sCJD affected individuals. As expected, little or no senile plaques were identified
in sCJD patients harboring lower levels of Aβ. Interestingly, sCJD patients harboring higher
amounts of Aβ have lower levels of PrPSc accumulation. This data can be interpreted in two
different ways. The first explanation is that the presence of Aβ inhibits misfolding and
accumulation of PrPSc. The second one is that part of the PrPSc molecules are used to induce
misfolding and aggregation of Aβ instead of further accumulation of PrP. The presence of both
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amyloidogenic species could have enhanced toxic effects, triggering clinical disease without
substantial accumulation of PrPSc. Due to the specific characteristics of these diseases, it is
possible that some clinical and pathological features of AD may camouflage sCJD [58,65]. In
a more extreme case, it could be possible to imagine that PrPSc formation, produced for example
by an infectious exposure may trigger Aβ misfolding and accumulation and lead to AD clinical
disease, instead of CJD. Thus, it could be interesting to study whether in countries with high
exposure to BSE (such as UK or France) there is an increased number of cases of AD or other
neurodegenerative diseases associated to protein misfolding and aggregation. It would also be
important to carry out more experiments in animal models to properly assess this important
issue.
Evidence In Vitro
The easiest way to test the hypothesis of cross-seeding is by in vitro aggregation assays.
Classical seeding assays show that the addition of a preformed seed reduced the extent of the
lag phase of aggregation in amyloidogenic proteins [27,29,66]. In addition, several reports
show that the extent of the nucleation phase of a specific protein could be reduced after the
addition of a heterologous seed [55,67]. This cross-seeding effect can be different according
to the protein/protein pair studied.
Subsequent to the clinical evidence described earlier in diabetes type-2 and AD patients [48],
in vitro seeding assays using amylin and Aβ were performed [67]. Interestingly, there is some
degree of sequence similarity between amylin and Aβ. If we add this information to the
previously mentioned reports that link AD and diabetes type-2 [48], it would be rational to
look for a putative interaction between both proteins. Seeding assays show that Aβ amyloids
are good seeds for amylin aggregation. However, the same report described that globular and
fibrillar aggregates of amylin have inert or very low effects on Aβ aggregation [67]. These
results are interesting if we consider the clinical data reported by Janson et al., where the
interaction between diabetes Type-2 in AD seems to work only in one direction [48].
Another important example of in vitro cross-seeding comes from studies involving α-synuclein
and Aβ [55,68]. The evidence in this case goes further, explaining a possible association
between different oligomeric aggregates [55]. Additionally, it is suggested that both proteins
could form annular structures able to generate pores in the cell membrane [55]. It is
hypothesized that these structures could produce cationic imbalance between intracellular and
extracellular spaces, leading to cell death events observed in this disorders.
By coupling seeding assays with other in vitro and in silico techniques, we could enormously
improve our knowledge regarding this important issue. However, in order to understand the
contribution of other events such us inflammation, signaling cascades and protein clearance
mechanisms in the progression of the disease, experimentation in animal models is absolutely
necessary.
Studies in Animal Models
The best way to analyze if two PMDs can cross-talk is by using animal models. Animal models
allow us to measure many pathological features in a controlled way and at different stages of
the disease. Several reports studying PMDs interactions in mouse models are available. Again,
the Aβ/α-synuclein pair is one of the best studied cases [55,69]. The results indicate that Aβ
enhances α-synuclein accumulation and neuronal deficits in a double transgenic mouse model
of AD and PD [69]. Considering their cellular distribution, interaction between Aβ extra-
cellular and α-synuclein (intra-cellular) seems unlikely. Nevertheless, immunoprecipitation
assays demonstrated the co-existence of both proteins in the mouse brain [55]. These data open
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new questions regarding the mechanisms of interaction for these particular proteins and their
consequences in pathological events.
The presence of Aβ aggregates and Tau neurofibrillary tangles is the major hallmark in AD.
It has been proposed for a long time that a putative interaction between both proteins could
enhance the clinical decline observed in AD patients. Two interesting pieces of evidence were
supplied in 2001 by Lewis et al. [70] and Gotz et al. [71]. These studies show that the
simultaneous presence of Aβ and Tau enhanced neurofribillary tangle formation in mouse
models. In the first approach, researchers crossed Tg2576 mice with transgenic mice expressing
a mutant form of Tau protein. They observed that Tg2576 and double transgenic mice develop
Aβ deposit at the same age, however neurofibrillary tangle deposition was significantly
enhanced compared to the single mutant Tau transgenic [70]. Interestingly, the increase in Tau
deposition was not correlated with areas rich in Aβ deposits. The second study consisted in the
inoculation of pre-formed Aβ42 fibrils in the brain of P301L Tau transgenic mice. As in the
previous report, the presence of misfolded Aβ in the brain of these mice increased Tau
deposition [71].
Considering the findings suggesting the co-existence of AD and sCJD, the study of a possible
link between both diseases is important. As suggested by Debatin et al. [58], the fact that the
AD phenotype could mask some sCJD cases makes this issue even more relevant. Since Aβ
and PrPSc have similar aggregation mechanisms and are located in the same tissue (brain) and
subcellular location (extracellular space), it is likely that these misfolded proteins may interact.
However, two recent reports suggest that PrPC biological function may be related to Aβ. First,
it was shown that PrPC could be a protective molecule in AD via β-secretase inhibition [72].
Second, it was shown that PrPC may be a receptor for Aβ oligomers, contributing to AD
neurodegeneration [73]. These somehow contradictory findings need to be further explored.
The stable characteristic of Aβ accumulation in transgenic mice [74–76] and the constant
incubation periods for prions [13] should make these studies easy to follow.
STRATEGIES FOR PMDs TREATMENT
It is well accepted that the misfolding process is the key event in the development of PMDs.
Therefore, therapeutic strategies targeted to the prevention of misfolding are today the most
promising for delaying the disease progression.
Currently, therapies for most PMDs are just palliative. It is possible that attacking the central
event in the disease (the misfolding and aggregation of the protein) could lead to more effective
disease-modifying therapies. In order to attack misfolding processes, different approaches have
been followed. One approach is attack specifically abnormally folded proteins that can later
on act as aggregation nuclei. Another strategy consists of inhibiting the misfolding process
itself. The former may allow depletion of putative seeds, whereas the latter might inhibit the
formation of newly converted units. Both approaches could help the endogenous protein
clearance systems, resulting in the total depletion of disease associated structures.
β-Sheet Breakers and Small Molecule Amyloid Inhibitors
One approach that has been used to discover small chemical inhibitors of protein misfolding
and aggregation has been the screening of large libraries of compounds using simple in vitro
assays [77–79]. The development of high throughput screening requires a robust, simple and
relevant in vitro assay to monitor compound activity. In the case of the search for compounds
able to prevent or reverse the protein misfolding cascade, the development of a screening assay
with these characteristics has been challenging. Nevertheless, there have been many small
chemical compounds that have been reported to inhibit protein misfolding and aggregation.
Some of these compounds came from screening, but several others were identified
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serendipitously or based on epidemiological studies which have suggested they may be active.
Some small molecules that that have been reported to prevent the misfolding and aggregation
of proteins involved in PMDs include Congo red and derivatives, curcumin and quinacrine,
among others (a more comprehensive list of compounds, including the specific references, can
be found in [77–80]).
Even though many molecules have been identified as strong inhibitors, the usefulness of these
small molecules is compromised by their lack of specificity, toxicity and their unclear
mechanism of action in most of the cases.
A strategy that has been more successful in identifying potential hit compounds is the rational
development of specific inhibitors based on the use of short peptides targeting the protein
region needed for protein-protein interaction [80,81]. The approach consists of synthesizing
short peptides combining a self-recognition motif with a β-sheet disrupting element. The self-
recognition domain is typically the region of the protein implicated in early misfolding and
protein-protein interaction. As disrupting elements, different groups have used distinct
strategies, including: the use of a bulky group (e.g cholyl) that sterically inhibit protein
aggregation; N-methylations (or N-alkylations) to generate peptides having a blocking face;
β-sheet breaker amino acids to disrupt beta-sheet conformation; and addition of charged
residues to reduce the hydrophobic interaction which trigger protein aggregation [80,81]. The
use of peptides as a therapy struggles with three main problems, namely transport across
biological membranes (i.e. the blood brain barrier and intestinal barrier), their rapid degradation
in the body and generation of an immune response. However, these problems can be minimized
by shortening the length of the peptide or by introducing chemical modifications [82]. The
usefulness of these types of molecules has been clearly shown by β-sheet breaker peptides in
models of AD and TSEs. In these studies it was shown that β-sheet breaker peptides decrease
the burden of misfolded protein aggregates in brain [83–85] and reduce the toxicity associated
to these proteins in cell cultures [83].
However, the recent identification of oligomers as the most toxic species in both diseases
[86–88] opens a new window to consider in the exploration and use of these therapeutic agents.
Following these findings it could be possible that the disruption of large aggregates into small
oligomeric units by these molecules could even increase the problem by releasing new toxic
species. These possibilities need to be experimentally evaluated in order to choose the right
therapeutic concentrations for the chosen molecule.
Vaccines
Several attempts for immunization against PMDs have been tried. Probably the best known is
the one tried by Elan pharmaceuticals against Aβ deposition [89]. The experimental strategy
included synthetic Aβ42 as immunogen in PDAPP transgenic mice, which spontaneously
generate AD plaques with age. Results showed an almost complete prevention of Aβ aggregates
and significant reduction of astrocytosis in mice immunized before plaque generation. Animals
treated with the Aβ vaccine at late stages of Aβ deposition showed a significant reduction in
amyloid burden compared to PBS treated controls. As expected, high levels of antibodies
against Aβ were found in the blood of Aβ42 treated mice. Unfortunately, clinical trials using
this vaccine in humans were not successful since some of the patients involved in the trial
developed meningeoencephalitis, leading in some of the cases to the death of the individuals
[90,91]. Currently, several approaches looking to reduce these adverse effects are under
development. They include, passive immunization or vaccination with non-fibrillary Aβ
derivatives and DNA immunization, among others [92–94].
Similar strategies have been tried for α-synuclein in Parkinson’s disease [95] and PrP in TSEs
[96]. For the latter we can mention the studies of Sigurdsson et al. [97] and Magri et al. [98],
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where the treatment with recombinant PrP or synthetic prion derived peptides increase the
incubation periods of mice and hamsters inoculated intraperitoneally with the 139A and 263K
prion strains, respectively. These results expand the concept applied for AD and confirm that
immunization using sequence specific peptides can decrease clinical features of PMDs.
Recently, an interesting approach using an attenuated Salmonella vaccine expressing mouse
PrP showed promising results in mice infected with 139A prions [99].
Conformational Antibodies
Current evidence supports the hypothesis that smaller and soluble oligomeric aggregates along
the pathway to form large fibrillar deposits could be the molecules mostly responsible for the
toxic effects observed in these maladies [86–88]. In this scenario, fibers could be acting as a
protective mechanism in order to trap these particles and encapsulate them in tissue. Recent
studies pioneered by the group of Charles Glabe showed the generation of antibodies specific
to diverse misfolded aggregated forms of amyloidogenic proteins, including oligomers and
fibrils [100]. Surprisingly, these antibodies are able to recognize oligomeric or fibrillar species
regardless of the sequence. The use of such antibodies may represent a universal treatment for
all amyloidogenic proteins and has the additional advantage that it targets exclusively the
structure that is thought to be the toxic one.
One of the main problems with using antibodies for treatment is their stability and delivery
into the CNS. Improvements in their delivery and stability could increase the use of these
molecules for the treatment of PMDs affecting the brain. However, this approach could be very
interesting in treating peripheral amyloidoses such as diabetes type-2. Additionally, the use of
these antibodies may contribute to increase our understanding of the amyloid biology and the
nature of the toxic species.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
This article describes common mechanisms associated with a variety of human diseases,
collectively called PMDs. Compelling evidence accumulated over the years indicates that the
key event in these diseases is the misfolding, aggregation and tissue accumulation of a protein.
The available evidence suggests that these proteins misfold and aggregate by a seeding -
nucleation mechanism. The formation of a stable seed, corresponding to an oligomer of the
protein adopting the misfolded structure, is the key event in the process. The oligomeric seed
is not only the most likely candidate for the toxic species, but also is able to accelerate the
polymerization of the aggregates. As such, seeds have the intrinsic ability to propagate the
misfolding and aggregation process. This provides a plausible model to explain the infectious
nature of TSEs, which is so far the only PMD considered transmissible. Importantly, the ability
of seeds composed of one protein to nucleate the aggregation of a different protein, through a
phenomenon termed cross-seeding, provides a mechanistic explanation for the relatively
common co-existence of more than one PMD in the same patient. In this article we also
discussed epidemiological and experimental evidence for the interaction of PMDs and their
implications for public health.
These topics open new issues in public health. The interaction between PMDs and the effect
that some of them can have as risk factors for more prevalent PMDs need to be considered. In
addition, the information gathered so far suggests that in all PMDs amiloidogenic structures
could be transmissible. Considering the high incidence of sporadic cases in some PMDs, it is
possible that a fraction of sporadic PMDs are originally generated by seeding or cross-seeding
mechanisms. Therefore, disease propagation by seeding and cross-seeding is an important topic
that needs to be further addressed in the years to come. A better understanding of these
mechanisms could help for rationale design of novel therapeutic and diagnostic methodologies
targeting these disorders.
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ABBREVIATIONS
AD Alzheimer’s disease
Aβ Amyloid β
BSE Bovine spongiform encephalopathy
GSS Gerstmann-Straüssler-Scheinker
PMDs Protein misfolding disorders
PD Parkinson’s disease
PrPC Cellular form of the prion protein
PrPSc Disease-associated form of the prion protein
sCJD sporadic Creutzfeldt Jacob Disease
TSEs Transmissible spongiform encephalopathies
vCJD Variant Creutzfeldt Jacob Disease
References
1. Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci 1999;24:329–332.
[PubMed: 10470028]
2. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev Neurosci
2003;4:49–60. [PubMed: 12511861]
3. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Ann Rev Neurosci
2001;24:519–550. [PubMed: 11283320]
4. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363–13383. [PubMed: 9811807]
5. Wadsworth JD, Collinge J. Update on human prion disease. Biochim Biophys Acta 2007;1772:598–
609. [PubMed: 17408929]
6. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999;354:317–323. [PubMed: 10440324]
7. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ, Lantos P. The same prion
strain causes vCJD and BSE. Nature 1997;389:448–450. [PubMed: 9333232]
8. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope
J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that ‘new variant’ CJD
is caused by the BSE agent. Nature 1997;389:498–501. [PubMed: 9333239]
9. Morales R, Abid K, Soto C. The prion strain phenomenon; molecular basis and unprecedented features.
Biochim Biophys Acta 2007;1772:681–691. [PubMed: 17254754]
10. Hill AF, Collinge J. Prion strains and species barriers. Contrib Microbiol 2004;11:33–49. [PubMed:
15077403]
11. Peretz D, Scott MR, Groth D, Williamson RA, Burton DR, Cohen FE, Prusiner SB. Strain-specified
relative conformational stability of the scrapie prion protein. Protein Sci 2001;10:854–863. [PubMed:
11274476]
12. Bartz JC, Bessen RA, McKenzie D, Marsh RF, Aiken JM. Adaptation and selection of prion protein
strain conformations following interspecies transmission of transmissible mink encephalopathy. J
Virol 2000;74:5542–5547. [PubMed: 10823860]
13. Castilla J, Morales R, Saa P, Barria M, Gambetti P, Soto C. Cell-free propagation of prion strains.
EMBO J 2008;27:2557–2566. [PubMed: 18800058]
Morales et al. Page 9
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
14. Sim VL, Caughey B. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils.
Neurobiol Aging. 2008 [Epub ahead of print].
15. Hill AF, Collinge J. Subclinical prion infection. Trends Microbiol 2003;11:578–584. [PubMed:
14659690]
16. Pattison, IH. Experiments with scrapie with special reference to the nature of the agent and the
pathology of the disease. In: Gajdusek, CJ.; Gibbs, CJ.; Alpers, MP., editors. Slow, Latent and
Temperate Virus Infections; NINDB Monograph. Vol. 2. U.S. Goberment Printing Office;
Washington, DC: 1965. p. 249-257.
17. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science
2007;318:930–936. [PubMed: 17991853]
18. Race R, Meade-White K, Raines A, Raymond GJ, Caughey B, Chesebro B. Subclinical scrapie
infection in a resistant species; persistence, replication, and adaptation of infectivity during four
passages. J Infect Dis 2002;186(Suppl 2):S166–S170. [PubMed: 12424693]
19. Scott M, Foster D, Mirenda C, Serban D, Coufal F, Walchli M, Torchia M, Groth D, Carlson G,
DeArmond SJ. Transgenic mice expressing hamster prion protein produce species-specific scrapie
infectivity and amyloid plaques. Cell 1989;59:847–857. [PubMed: 2574076]
20. Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang SL, Serban D,
Carlson GA. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie
prion replication. Cell 1990;63:673–686. [PubMed: 1977523]
21. Moore RA, Vorberg I, Priola SA. Species barriers in prion diseases--brief review. Arch Virol 2005;
(Suppl):187–202.
22. Collee JG, Bradley R. BSE: a decade on--Part I. Lancet 1997;349:636–641. [PubMed: 9057745]
23. Collee JG, Bradley R. BSE: a decade on--Part 2. Lancet 1997;349:715–721. [PubMed: 9078212]
24. Kirkwood JK, Cunningham AA. Epidemiological observations on spongiform encephalopathies in
captive wild animals in the British Isles. Vet Rec 1994;135:296–303. [PubMed: 7817514]
25. Pearson GR, Wyatt JM, Gruffydd-Jones TJ, Hope J, Chong A, Higgins RJ, Scott AC, Wells GA.
Feline spongiform encephalopathy: fibril and PrP studies. Vet Rec 1992;131:307–310. [PubMed:
1279883]
26. Bons N, Mestre-Frances N, Belli P, Cathala F, Gajdusek DC, Brown P. Natural and experimental
oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad
Sci USA 1999;96:4046–4051. [PubMed: 10097160]
27. Jarrett JT, Lansbury PT Jr. Seeding “one-dimensional crystallization” of amyloid; a pathogenic
mechanism in Alzheimer’s disease and scrapie? Cell 1993;73:1055–1058. [PubMed: 8513491]
28. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free
formation of protease-resistant prion protein. Nature 1994;370:471–474. [PubMed: 7913989]
29. Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein
aggregates. Trends Biochem Sci 2006;31:150–155. [PubMed: 16473510]
30. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett 2001;498:204–207.
[PubMed: 11412858]
31. Jarrett JT, Lansbury PT Jr. Amyloid fibril formation requires a chemically discriminating nucleation
event; studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry
1992;31:12345–12352. [PubMed: 1463722]
32. Gajdusek DC. Nucleation of Amyloidogenesis in Infections and Noninfectious Amyloidoses of Brain.
Ann NY Acad Sci 1994;724:173–190. [PubMed: 8030940]
33. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois
B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA,
Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum
RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK. DLB and
PDD boundary issues; diagnosis, treatment, molecular pathology, and biomarkers. Neurology
2007;68:812–819. [PubMed: 17353469]
34. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer-
type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 1998;96:116–122.
[PubMed: 9705125]
Morales et al. Page 10
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
35. Tsuchiya K, Yagishita S, Ikeda K, Sano M, Taki K, Hashimoto K, Watabiki S, Mizusawa H.
Coexistence of CJD and Alzheimer’s disease; an autopsy case showing typical clinical features of
CJD. Neuropathology 2004;24:46–55. [PubMed: 15068172]
36. Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM. Observation of sequence
specificity in the seeding of protein amyloid fibrils. Protein Sci 2004;13:1933–1938. [PubMed:
15215533]
37. Lundmark K, Westermark GT, Olsen A, Westermark P. Protein fibrils in nature can enhance amyloid
protein A amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA
2005;102:6098–6102. [PubMed: 15829582]
38. Brown P, Jannotta F, Gibbs CJ Jr, Baron H, Guiroy DC, Gajdusek DC. Coexistence of Creutzfeldt-
Jakob disease and Alzheimer’s disease in the same patient. Neurology 1990;40:226–228. [PubMed:
2405293]
39. Miyazono M, Kitamoto T, Iwaki T, Tateishi J. Colocalization of prion protein and beta protein in the
same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol (Berl)
1992;83:333–339. [PubMed: 1349451]
40. Muramoto T, Kitamoto T, Koga H, Tateishi J. The coexistence of Alzheimer’s disease and
Creutzfeldt-Jakob disease in a patient with dementia of long duration. Acta Neuropathol (Berl)
1992;84:686–689. [PubMed: 1471476]
41. Iida T, Doh-Ura K, Kawashima T, Abe H, Iwaki T. An atypical case of sporadic Creutzfeldt-Jakob
disease with Parkinson’s disease. Neuropathology 2001;21:294–297. [PubMed: 11837536]
42. Preusser M, Strobel T, Gelpi E, Eiler M, Broessner G, Schmutzhard E, Budka H. Alzheimer-type
neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting.
J Neurol Neurosurg Psychiatry 2006;77:413–416. [PubMed: 16484658]
43. Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink
encephalopathy in hamsters. J Gen Virol 1992;73(Pt 2):329–334. [PubMed: 1531675]
44. Stephenson DA, Chiotti K, Ebeling C, Groth D, DeArmond SJ, Prusiner SB, Carlson GA. Quantitative
trait loci affecting prion incubation time in mice. Genomics 2000;69:47–53. [PubMed: 11013074]
45. Browning SR, Mason GL, Seward T, Green M, Eliason GA, Mathiason C, Miller MW, Williams ES,
Hoover E, Telling GC. Transmission of prions from mule deer and elk with chronic wasting disease
to transgenic mice expressing cervid PrP. J Virol 2004;78:13345–13350. [PubMed: 15542685]
46. Groschup MH, Buschmann A. Rodent models for prion diseases. Vet Res 2008;39:32. [PubMed:
18284909]
47. Windl O, Buchholz M, Neubauer A, Schulz-Schaeffer W, Groschup M, Walter S, Arendt S, Neumann
M, Voss AK, Kretzschmar HA. Breaking an absolute species barrier; transgenic mice expressing the
mink PrP gene are susceptible to transmissible mink encephalopathy. J Virol 2005;79:14971–14975.
[PubMed: 16282497]
48. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes
in Alzheimer disease. Diabetes 2004;53:474–481. [PubMed: 14747300]
49. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk
of dementia; The Rotterdam Study. Neurology 1999;53:1937–1942. [PubMed: 10599761]
50. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s
disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635–641.
[PubMed: 11581097]
51. Landin K, Blennow K, Wallin A, Gottfries CG. Low blood pressure and blood glucose levels in
Alzheimer’s disease. Evidence for a hypometabolic disorder? J Intern Med 1993;233:357–363.
[PubMed: 8463769]
52. Nielson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW. Apolipoprotein-E
genotyping of diabetic dementia patients; is diabetes rare in Alzheimer’s disease? J Am Geriatr Soc
1996;44:897–904. [PubMed: 8708297]
53. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for
Alzheimer’s disease; a population-based case-control study. Neurology 1991;41:1393–1397.
[PubMed: 1891088]
Morales et al. Page 11
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
54. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL,
Harris T, Chen R, White LR. Longitudinal association of vascular and Alzheimer’s dementias,
diabetes, and glucose tolerance. Neurology 1999;52:971–975. [PubMed: 10102414]
55. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E,
Trejo M, Platoshyn O, Yuan JX, Masliah E. Mechanisms of hybrid oligomer formation in the
pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS ONE 2008;3:e3135.
[PubMed: 18769546]
56. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra
SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL,
Lovestone S, Collerton D, Jansen EN, Ballard C, De Vos RA, Wilcock GK, Jellinger KA, Perry RH.
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB);
report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124. [PubMed:
8909416]
57. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, Rey MJ, Ribalta T. Prion protein expression in
senile plaques in Alzheimer’s disease. Acta Neuropathol (Berl) 2001;101:49–56. [PubMed:
11194941]
58. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M. Association between deposition
of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener
Dis 2008;5:347–354. [PubMed: 18349519]
59. Paquet C, Privat N, Kaci R, Polivka M, Dupont O, Haik S, Laplanche JL, Hauw JJ, Gray F. Cerebral
amyloid angiopathy with co-localization of prion protein and beta-amyloid in an 85-year-old patient
with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 2008;116:567–573. [PubMed:
18551298]
60. Leuba G, Saini K, Savioz A, Charnay Y. Early-onset familial Alzheimer disease with coexisting beta-
amyloid and prion pathology. JAMA 2000;283:1689–1691. [PubMed: 10755493]
61. Schwarze-Eicker K, Keyvani K, Gortz N, Westaway D, Sachser N, Paulus W. Prion protein (PrP(c))
promotes beta-amyloid plaque formation. Neurobiol Aging 2005;26:1177–1182. [PubMed:
15917101]
62. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier
J, Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion
protein. Science 1997;275:402–405. [PubMed: 8994041]
63. Manuelidis L, Sklaviadis T, Manuelidis EE. Evidence suggesting that PrP is not the infectious agent
in Creutzfeldt-Jakob disease. EMBO J 1987;6:341–347. [PubMed: 3556164]
64. Collinge J, Owen F, Poulter M, Leach M, Crow TJ, Rossor MN, Hardy J, Mullan MJ, Janota I, Lantos
PL. Prion dementia without characteristic pathology. Lancet 1990;336:7–9. [PubMed: 1973256]
65. Manuelidis EE, Manuelidis L. A transmissible Creutzfeldt-Jakob disease-like agent is prevalent in
the human population. Proc Natl Acad Sci, USA 1993;90:7724–7728. [PubMed: 8356076]
66. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of
amyloid beta-protein fibrils; detection of nuclei and quantitation of rate constants. Proc Natl Acad
Sci USA 1996;93:1125–1129. [PubMed: 8577726]
67. O’Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced
by heterologous fibrils. J Biol Chem 2004;279:17490–17499. [PubMed: 14752113]
68. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide
and alpha synuclein; molecular mechanisms in overlapping pathology of Alzheimer’s and
Parkinson’s in dementia with Lewy body disease. Neurochem Res 2006;31:1153–1162. [PubMed:
16947080]
69. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. Beta-amyloid
peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model
linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 2001;98:12245–
12250. [PubMed: 11572944]
70. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager
D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic
mice expressing mutant tau and APP. Science 2001;293:1487–1491. [PubMed: 11520987]
Morales et al. Page 12
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
71. Gotz J, Chen F, Van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic
mice induced by Abeta 42 fibrils. Science 2001;293:1491–1495. [PubMed: 11520988]
72. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ,
Hooper NM. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid
precursor protein. Proc Natl Acad Sci USA 2007;104:11062–11067. [PubMed: 17573534]
73. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates
impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457:1128–1132.
[PubMed: 19242475]
74. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative
memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99–
102. [PubMed: 8810256]
75. Van DD, De Deyn PP. Drug discovery in dementia; the role of rodent models. Nat Rev Drug Discov
2006;5:956–970. [PubMed: 17080031]
76. Dodart JC, May P. Overview on rodent models of Alzheimer’s disease. Curr Protoc Neurosci
2005;Chapter 9
77. De LE, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V. Pharmaceutical strategies against
amyloidosis; old and new drugs in targeting a “protein misfolding disease”. Curr Med Chem
2004;11:1065–1084. [PubMed: 15078166]
78. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 2003;426:905–
909. [PubMed: 14685252]
79. Soto C, Martin Z. Therapeutic strategies against protein misfolding in neurodegenerative diseases.
Expert Opin Drug Discov 2009;4:71–84.
80. Mason JM, Kokkoni N, Stott K, Doig AJ. Design strategies for anti-amyloid agents. Curr Opin Struct
Biol 2003;13:526–532. [PubMed: 12948784]
81. Estrada LD, Soto C. Peptide inhibitors of protein misfolding and aggregation. Curr Pharm Des
2006;12:2557–2568. [PubMed: 16842178]
82. Adessi C, Soto C. Converting a peptide into a drug; Strategies to improve stability and bioavailability.
Curr Med Chem 2002;9:963–978. [PubMed: 11966456]
83. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides
inhibit fibrillogenesis in a rat brain model of amyloidosis; Implications for Alzheimer’s therapy. Nat
Med 1998;4:822–826. [PubMed: 9662374]
84. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA,
Van Leuven F, Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model
of Alzheimer’s disease by treatment with a beta-sheet breaker peptide. FASEB J 2002;16:860–862.
[PubMed: 11967228]
85. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Harris
DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational
changes by synthetic beta-sheet breaker peptides. Lancet 2000;355:192–197. [PubMed: 10675119]
86. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration; separating the
responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267–298.
[PubMed: 12704221]
87. Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common
mechanism of pathogenesis. Neurology 2006;66:S74–S78. [PubMed: 16432151]
88. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration; lessons from the Alzheimer’s
amyloid beta-peptide. Nat Rev Molec Cell Biol 2007;8:101–112. [PubMed: 17245412]
89. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K,
Khan K, Kholodenko D, Lee M, Liao ZM, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G,
Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization
with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature
1999;400:173–177. [PubMed: 10408445]
90. Spinney L. Update on Elan vaccine for Alzheimer’s disease. Lancet Neurol 2004;3:5.
91. Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease; the end of the beginning. Nat Rev
Neurosci 2002;3:824–828. [PubMed: 12360327]
Morales et al. Page 13
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
92. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B,
Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s
disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004;24:6277–6282.
[PubMed: 15254082]
93. Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J, Wollmer MA, Nitsch RM,
Moelling K. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a
mouse model of Alzheimer’s disease. J Mol Med 2004;82:706–714. [PubMed: 15241501]
94. Okura Y, Matsumoto Y. DNA vaccine therapy for Alzheimer’s disease; present status and future
direction. Rejuvenation Res 2008;11:301–308. [PubMed: 18442321]
95. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein
J, Chilcote T, Games D, Schenk D. Effects of alpha-synuclein immunization in a mouse model of
Parkinson’s disease. Neuron 2005;46:857–868. [PubMed: 15953415]
96. Sigurdsson EM, Wisniewski T. Promising developments in prion immunotherapy. Expert Rev
Vaccines 2005;4:607–610. [PubMed: 16221061]
97. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B,
Wisniewski T. Immunization delays the onset of prion disease in mice. Am J Pathol 2002;161:13–
17. [PubMed: 12107084]
98. Magri G, Clerici M, Dall’Ara P, Biasin M, Caramelli M, Casalone C, Giannino ML, Longhi R,
Piacentini L, Della Bella S, Gazzuola P, Martino PA, Della Bella S, Pollera C, Puricelli M, Servida
F, Crescio I, Boasso A, Ponti W, Poli G. Decrease in pathology and progression of scrapie after
immunisation with synthetic prion protein peptides in hamsters. Vaccine 2005;23:2862–2868.
[PubMed: 15780734]
99. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Rubenstein R,
Brown DR, Sy MS, Chabalgoity JA, Sigurdsson EM, Wisniewski T. Mucosal vaccination delays or
prevents prion infection via an oral route. Neuroscience. 2005
100. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common
structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science
2003;300:486–489. [PubMed: 12702875]
Morales et al. Page 14
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. Generation of misfolded prions in TSEs
PrPSc, the disease-associated form of the prion protein, is able to impose its structure to a
normally produced protein, termed PrPC. As result, an exponential generation of misfolded
prions is obtained. PrPSc has been associated with several cytotoxic events in vitro and in
vivo. The accumulation of the abnormal protein in the brain leads to clinical decline, which
invariably ends in the death of the affected individuals.
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Fig. 2. Seeding and cross-seeding mechanisms in Protein Misfolding Disorders
A variety of factors, including mutations, abnormal biosynthesis, changes in cellular
environment or impairments on the quality control machinery, induce the initial misfolding of
normally folded proteins. Misfolded proteins become stabilized upon oligomerization and
formation of long fibrillar amyloid aggregates. Preformed seeds have been described to speed
this process in vitro and in vivo. In addition, the presence of misfolded nuclei could enhance
the aggregation of other amyloids, a phenomenon known as cross-seeding.
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